Startseite>>Signaling Pathways>> Others>>Methyocarbamol

Methyocarbamol (Synonyms: AHR 85, Guaiacol Glyceryl Ether Carbamate, Guaiphenesin Carbamate, NSC 170960)

Katalog-Nr.GC16339

Methyocarbamol ist ein oral wirksames zentrales Muskelrelaxans und blockiert den muskulÄren Nav1.4-Kanal.

Products are for research use only. Not for human use. We do not sell to patients.

Methyocarbamol Chemische Struktur

Cas No.: 532-03-6

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
57,00 $
Auf Lager
50mg
47,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Methocarbamol is a central muscle relaxant used to treat skeletal muscle spasms.Target: Carbonic AnhydraseMethocarbamol is the carbamate of guaifenesin, but does not produce guaifenesin as a metabolite, because the carbamate bond is not hydrolyzed metabolically; metabolism is by Phase I ring hydroxylation and O-demethylation, followed by Phase II conjugation. All the major metabolites are unhydrolyzed carbamates. Methocarbamol is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm [1, 2].

References:
[1]. Bruce, R.B., L.B. Turnbull, and J.H. Newman, Metabolism of methocarbamol in the rat, dog, and human. J Pharm Sci, 1971. 60(1): p. 104-6.
[2]. Sica, D.A., et al., Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol, 1990. 39(2): p. 193-4.

Bewertungen

Review for Methyocarbamol

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Methyocarbamol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.